<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE301nnn/GSE301853/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301853</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Restoring NK cell cytotoxicity post-cryopreservation via synthetic IL-2-presenting cells</name><description>Natural killer (NK) cells are critical components of the first-line immune defense, responsible for eliminating tumorigenic cells. NK cell-based adoptive immunotherapy has gained increasing attention; however, cryopreservation, a standard technique for NK cell storage, significantly impairs NK cell cytotoxicity, particularly in physiological 3D environments. Here, we demonstrate that short-term co-culture with effector T cells markedly enhances NK cell motility and killing functionality. Notably, a brief 1-day co-culture is sufficient to restore cryopreservation-impaired NK cell functionality in 3D environments. This enhancement requires direct contact between T cells and NK cells, which facilitates localized high concentrations of IL-2 at the cell contact sites. To develop a controlled, donor-independent solution, we demonstrate that synthetic T cells with surface-bound IL-2 or IL-15 exhibit superior efficiency in revitalizing cryopreserved NK cells. These findings uncover a previously unrecognized role for physical contact-mediated local IL-2 or IL-15 signaling and provide an efficient, cost-effective, and tunable strategy to rescue NK cell functionality post-cryopreservation, paving the way for more scalable, potent, and clinically viable NK cell-based immunotherapies.</description><dates><publication>2026/07/06</publication></dates><accession>GSE301853</accession><cross_references><GSM>GSM9090827</GSM><GSM>GSM9090828</GSM><GSM>GSM9090825</GSM><GSM>GSM9090826</GSM><GSM>GSM9090823</GSM><GSM>GSM9090824</GSM><GSM>GSM9090822</GSM><GSM>GSM9090830</GSM><GSM>GSM9090829</GSM><GSM>GSM9090819</GSM><GPL>24676</GPL><GSE>301853</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>